SER Serina: Forward P/S Multiple

Serina Therapeutics - graphic logo of issuer SER

Serina Therapeutics, Inc. (SER) develops polymer delivery systems for Parkinson's disease medications, ensuring stable demand and long-term margins. The organization's forward P/S ratio visualizes market value relative to expected revenues, with the metric settling at 311.20. Patents for drug transport methods block access for smaller players, although the lack of current sales and the clinical trial stage deprive the company of pricing power.

SER (Serina Therapeutics) Market Cap to Future Revenue Ratio history from 03/28/2024 to 11/17/2026

SER (serinatherapeutics.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Summary company analysis:Serina Pharma SER
Product sample of Serina Therapeutics, Inc.

The development of the POZ platform for Parkinson's disease therapy transitions Serina Therapeutics, Inc. (SER) into an active growth phase, where market value is assessed through future revenue streams. The forward P/S trajectory reflects expectations regarding business model viability and debt load, allowing investors to balance the potential for scaling innovations against the risk of capital freeze in highly leveraged assets.